{"name":"TEVA PHARMS USA","slug":"teva-pharms-usa","ticker":"","exchange":"","domain":"tevapharmsusa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2005-01-01","label":"Mycamine first approved","drug":"Mycamine","drugSlug":"micafungin","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Istodax first approved","drug":"Istodax","drugSlug":"romidepsin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Mycamine","genericName":"MICAFUNGIN","slug":"micafungin","indication":"Candida Peritonitis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Istodax","genericName":"ROMIDEPSIN","slug":"romidepsin","indication":"Cutaneous T-cell lymphoma (CTCL)","status":"marketed"}]}],"pipeline":[{"name":"Mycamine","genericName":"MICAFUNGIN","slug":"micafungin","phase":"marketed","mechanism":"ATP-binding cassette sub-family G member 2","indications":["Candida Peritonitis","Candidal septicemia","Candidemia","Candidiasis of the esophagus","Disseminated candidiasis"],"catalyst":""},{"name":"Istodax","genericName":"ROMIDEPSIN","slug":"romidepsin","phase":"marketed","mechanism":"Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells.","indications":["Cutaneous T-cell lymphoma (CTCL)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}